These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36852672)

  • 1. The inflammatory burden index is a superior systemic inflammation biomarker for the prognosis of non-small cell lung cancer.
    Xie H; Ruan G; Wei L; Deng L; Zhang Q; Ge Y; Song M; Zhang X; Lin S; Liu X; Yang M; Song C; Zhang X; Shi H
    J Cachexia Sarcopenia Muscle; 2023 Apr; 14(2):869-878. PubMed ID: 36852672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammatory burden as a prognostic biomarker for cancer.
    Xie H; Ruan G; Ge Y; Zhang Q; Zhang H; Lin S; Song M; Zhang X; Liu X; Li X; Zhang K; Yang M; Tang M; Song CH; Shi H
    Clin Nutr; 2022 Jun; 41(6):1236-1243. PubMed ID: 35504166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive comparative analysis of prognostic value of serum systemic inflammation biomarkers for colorectal cancer: Results from a large multicenter collaboration.
    Xie H; Ruan G; Wei L; Zhang H; Ge Y; Zhang Q; Song M; Zhang X; Liu X; Lin S; Yang M; Hu C; Tang M; Deng L; Hu W; Shi H
    Front Immunol; 2022; 13():1092498. PubMed ID: 36685502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy.
    Zhang Y; Chen Z; Jin F; Guo D; Chen Q; Liu Z; Ji S; Gao G
    Mediators Inflamm; 2021; 2021():2910892. PubMed ID: 34744510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive comparison of the prognostic value of systemic inflammation biomarkers for cancer cachexia: a multicenter prospective study.
    Xie H; Ruan G; Wei L; Zhang H; Ge Y; Zhang Q; Lin S; Song M; Zhang X; Liu X; Yang M; Tang M; Song CH; Deng L; Shi H
    Inflamm Res; 2022 Nov; 71(10-11):1305-1313. PubMed ID: 35962796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AWGC2023 cachexia consensus as a valuable tool for predicting prognosis and burden in Chinese patients with cancer.
    Xie H; Wei L; Ruan G; Zhang H; Shi J; Lin S; Liu C; Liu X; Zheng X; Chen Y; Chen J; Shi H
    J Cachexia Sarcopenia Muscle; 2024 Oct; 15(5):2084-2093. PubMed ID: 39192568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic value of the combination of body composition and systemic inflammation in patients with cancer cachexia.
    Xie HL; Ruan GT; Wei L; Zhang Q; Ge YZ; Song MM; Zhang X; Lin SQ; Liu XY; Zhang XW; Li XR; Zhang KP; Hu CL; Yang M; Tang M; Song CH; Cong MH; Weng M; Li ZN; Li W; Wang KH; Shi HP
    J Cachexia Sarcopenia Muscle; 2023 Apr; 14(2):879-890. PubMed ID: 36872512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A Prognostic Model of Elderly Patients with Non-small Cell Lung Cancer 
Based on Geriatric Nutritional Risk Index].
    Zhang X; Xiong Y; Xu A
    Zhongguo Fei Ai Za Zhi; 2023 Jul; 26(7):497-506. PubMed ID: 37653013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review.
    Jafri SH; Shi R; Mills G
    BMC Cancer; 2013 Mar; 13():158. PubMed ID: 23530866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of the fat-free mass index-based cachexia index in patients with colorectal cancer.
    Qin Y; Xie H; Liu T; Zhang H; Liu C; Li X; Bu Z; Liu X; Lin S; Chen Y; Zheng X; Zhao H; Shi J; Shi H
    Sci Rep; 2024 Oct; 14(1):24390. PubMed ID: 39420045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrinogen-to-albumin ratio (FAR) is the best biomarker for the overall survival of patients with non-small-cell lung cancer.
    Ma S; Wang L
    Front Oncol; 2024; 14():1396843. PubMed ID: 38978733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between plasma circulating cell-free DNA concentration and treatment outcomes including prognosis in patients with advanced non-small cell lung cancer.
    Peng WW; Liu Y; Sha HH; Wen SD; Fang Y; Zhou GR
    BMC Pulm Med; 2023 Sep; 23(1):348. PubMed ID: 37710221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulated MicroRNA 148b expression as predictive biomarker and its prognostic significance associated with clinicopathological features in non-small-cell lung cancer patients.
    Ghasemkhani N; Shadvar S; Masoudi Y; Talaei AJ; Yahaghi E; Goudarzi PK; Shakiba E
    Diagn Pathol; 2015 Sep; 10():164. PubMed ID: 26377406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Significance of the Preoperative Inflammatory Burden Index in Esophageal Cancer.
    Yin C; Okugawa Y; Kitajima T; Shimura T; Ma R; Kawamura M; Yoshiyama S; Okita Y; Ohi M; Toiyama Y
    Oncology; 2024; 102(7):556-564. PubMed ID: 38142688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic Immune-inflammation Index Predicts Survival of Patients After Curative Resection for Non-small Cell Lung Cancer.
    Tomita M; Ayabe T; Maeda R; Nakamura K
    In Vivo; 2018; 32(3):663-667. PubMed ID: 29695576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The advanced lung cancer inflammation index (ALI) predicted the postoperative survival rate of patients with non-small cell lung cancer and the construction of a nomogram model.
    Ma S; Li Z; Wang L
    World J Surg Oncol; 2024 Jun; 22(1):158. PubMed ID: 38877553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.
    Tong YS; Tan J; Zhou XL; Song YQ; Song YJ
    J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic and prognostic value of serum thioredoxin and DJ-1 in non-small cell lung carcinoma patients.
    Fan J; Yu H; Lv Y; Yin L
    Tumour Biol; 2016 Feb; 37(2):1949-58. PubMed ID: 26334622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Prognostic Role of Blood Inflammatory Biomarkers and EGFR Mutation Status in Stage IIIA/N2 Non-Small Cell Lung Cancer Patients Treated With Trimodality Therapy.
    Yang H; Wang K; Li B; Li S; Li Y; Yuan L
    Front Oncol; 2021; 11():707041. PubMed ID: 34917497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.